Something you're not accounting for is the Anavex trial is for Mild to Moderate AD patients. They decline much faster than just Mild AD patients. Make sure you're comparing the Anavex trial with other trials that include Mild to Moderate patients only. And also make sure the mean ages of the two groups you're comparing are the same, as that also has big effect on rate of decline. And remember, this Ph 2A trial used non-optimized dosing! The first 5 weeks of the trial were different the following 52 weeks. Those first 5 weeks including IV administration of 2-73 at only 3 or 5mg and a 12 day washout period after the first 12 days of the trial. 7 patients were not on donepezil. Those that were on donepezil, were probably on it for more than a year, so how effective the donepezil was at that point is anyone's guess.
MMSE is subject to variability. Anavex also used Cogstate, ERP's and P3a amplitude using the trademark Cognision system, Ham D, and ADCS ADL assessments. Changes in scores for all assessments were consistent with each other over time and were also dose and blood concentration dependent.
To partly assess cognition in the Ph 2/3, Anavex will be using ADAS Cog
Market Data 
Markets 
AI
